Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
Abstract Background Two antifibrotic drugs, nintedanib and pirfenidone, are available for treatment of idiopathic pulmonary fibrosis (IPF). Although efficacy and adverse events have been well studied, little is known about patient experiences with these drugs. We aimed to systematically and quantita...
Main Authors: | C. C. Moor, R. L. M. Mostard, J. C. Grutters, P. Bresser, J. G. J. V. Aerts, C. D. Dirksen, M. L. Kimman, M. S. Wijsenbeek |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12931-020-01458-1 |
Similar Items
-
Improvement in Subjective Symptoms and Tolerability in Response to Nintedanib Treatment in Elderly Patients with Idiopathic Pulmonary Fibrosis
by: Takayuki Takeda, et al.
Published: (2020-03-01) -
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
by: Manon Belhassen, et al.
Published: (2021-05-01) -
Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis
by: Catharina C. Moor, et al.
Published: (2017-12-01) -
Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
by: Gareth Hughes, et al.
Published: (2016-09-01) -
South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-12-01)